Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

References

• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• AmbrosioniEPharmacoeconomics of hypertension management: the place of combination therapyPharmacoeconomics2001193374711383751
   PubMed Web of Science ®Google Scholar
• AmerJHypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study)J Hypertens2002207798411910316
   PubMed Web of Science ®Google Scholar
• AndersonAMorganTOInteraction of enalapril with sodium restriction, diuretics, and slow-channel calcium-blocking drugsNephron199055Suppl 17022345592
   PubMedGoogle Scholar
• BrunnerHRGavrasHWaeberBEnhancement of diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockadeClin Exp Hypertens19802639576253243
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med200516511475215911728
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe JNC 7 ReportThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureJAMA200328925607112748199
   PubMed Web of Science ®Google Scholar
• ConlinPRSpenceJDWilliamsBAngiotensin II antagonists for hypertension: are there differences in efficacy?Am J Hypertens2000134182610821345
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRde FaireUThe Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, design, and methodsAm J Hypertens199710705139234823
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBJuliusSCharacteristics of 9194 patients with left ventricular hypertrophy: The LIFE StudyHypertension199832989979856962
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSEDiuretics in the LIFE studyLancet2004364413415288732
   PubMed Web of Science ®Google Scholar
• DevereuxRBDahlöfBGerdtsERegression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) TrialCirculation200411014566215326072
   PubMed Web of Science ®Google Scholar
• DevereuxRBde FaireUFyhrquistFBlood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyCurr Med Res Opin2007232597017288679
   PubMed Web of Science ®Google Scholar
• DevereuxRBDahlofBPotential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyCurr Med Res Opin20072344345717288698
   PubMed Web of Science ®Google Scholar
• DeziiCMA retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertensionManag Care20009Suppl 92611729417
   PubMedGoogle Scholar
• ElliottWJCalhounDADeLuccaPTLosartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trialClin Ther20012311667911558856
   PubMed Web of Science ®Google Scholar
• FieldsLEBurtVLCutlerJAThe burden of adult hypertension in the United States 1999 to 2000: A rising tideHypertension20044439840415326093
   PubMed Web of Science ®Google Scholar
• GleimGWRubinoJZhangHA randomized, double-blind trial of the antihypertensive efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg combination compared with losartan 100 mg monotherapy in the treatment of mild-to-severe essential hypertensionClin Ther20062816394817157119
   PubMed Web of Science ®Google Scholar
• GoldsteinLBAdamsRAlbertsMJPrimary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working GroupStroke200637158363316675728
   PubMed Web of Science ®Google Scholar
• GradmanAHBradyWEGazdickLPA multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertensionClin Ther20022410496112182251
   PubMed Web of Science ®Google Scholar
• Guidelines Committee2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20036101153
   Google Scholar
• HajjarIKotchenTATrends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000JAMA200329019920612851274
   PubMed Web of Science ®Google Scholar
• HallWDPharmacologic therapy of hypertension in blacksJ Clin Hypertens19873Suppl 3108S113S3312505
   PubMedGoogle Scholar
• HanssonLLindholmLHNiskanenLEffect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialLancet1999353611610030325
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar
• HoieggenAAldermanMHKjeldsenSEThe impact of serum uric acid on cardiovascular outcomes in the LIFE studyKidney Int2004651041914871425
   PubMed Web of Science ®Google Scholar
• IbsenHWachtellKOlsenMHDoes albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudyJ Hypertens20042218051115311110
   PubMed Web of Science ®Google Scholar
• JuliusSAldermanMHBeeversGCardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. The LIFE studyJ Am Coll Cardiol2004a4310475515028365
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet2004b36320223115207952
   PubMed Web of Science ®Google Scholar
• KizerJRHoieggenAAldermanMHSerum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) studyJ Am Coll Cardiol2004435 suppl A475A
   Web of Science ®Google Scholar
• KizerJRDahlöfBKjeldsenSEStroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyHypertension200545465215583076
   PubMed Web of Science ®Google Scholar
• KizerJRDevereuxRBRegression of left ventricular hypertrophy: lodestar to stroke prevention in the treatment of hypertension?Am J Hypertens20061943944416647610
   PubMed Web of Science ®Google Scholar
• KjeldsenSEJuliusSHednerTStroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trialsBlood Press200110190211800055
   PubMed Web of Science ®Google Scholar
• KjeldsenSEOsIHoieggenAFixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazideAm J Cardiovasc Drugs2005a5172215631534
   PubMedGoogle Scholar
• KjeldsenSELylePATershakovecAMTargeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersExpert Opin Emerging Drugs2005b1072945
   PubMedGoogle Scholar
• LindholmLHIbsenHBorch-JohnsenKRisk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyJ Hypertens20022018798612195132
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032115637412872052
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens2003218758612714861
   PubMed Web of Science ®Google Scholar
• MacGregorGAMarkanduNDSingerDRModerate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind studyBMJ198729453143103761
   PubMed Web of Science ®Google Scholar
• ManciaGPrevention and treatment of stroke in patients with hypertensionClin Ther2004266314815220009
   PubMed Web of Science ®Google Scholar
• MulrowCLauJCornellJPharmacotherapy for hypertension in the elderlyCochrane Database Syst Rev2000CD00002810796688
   PubMedGoogle Scholar
• NavisGde JongPEDonkerAModerate sodium restriction in hypertensive subjects: renal effects of ACE-inhibitionKidney Int19873181593033389
   PubMed Web of Science ®Google Scholar
• OkinPMDevereuxRBJernSRegression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyCirculation20031086849012885747
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackLancet200135810334111589932
   PubMed Web of Science ®Google Scholar
• PsatyBMLumleyTFurbergCDHealth outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysisJAMA200328925344412759325
   PubMed Web of Science ®Google Scholar
• RosamondWFlegalKFridayGHeart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation2007115e6917117194875
   PubMed Web of Science ®Google Scholar
• SadoshimaJNovel AT(1)-receptor-independent functions of losartanCirc Res200290754611964366
   PubMed Web of Science ®Google Scholar
• SalernoCMDemopoulosLMukherjeeRCombination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertensionJ Clin Hypertens (Greenwich)200466142015538094
   PubMedGoogle Scholar
• SassanoPChatellierGBillaudEComparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril aloneJ Cardiovasc Pharmacol19891331492468963
   PubMed Web of Science ®Google Scholar
• SchiffrinELParkJBIntenganHDCorrection of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartanCirculation20001011653910758046
   PubMed Web of Science ®Google Scholar
• SchraderJLudersSKulschewskiAMorbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)Stroke20053612182615879332
   PubMed Web of Science ®Google Scholar
• SingerDRMarkanduNDCappuccioFPReduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazideHypertension199525104247737713
   PubMed Web of Science ®Google Scholar
• SleightPPouleurHZannadFBenefits, challenges, and registerability of the polypillEur Heart J2006271651616603580
   PubMed Web of Science ®Google Scholar
• StierCTAdlerLALevineSStroke prevention by losartan in stroke-prone spontaneously hypertensive ratsJ Hypertens199311S3742
   Google Scholar
• StrausSEMajumdarSRMcAlisterFANew evidence for stroke prevention: scientific reviewJAMA200228813889512234233
   PubMed Web of Science ®Google Scholar
• SvenssonPde FaireUSleightPYusufSOstergrenJComparative effects of ramipril on ambulatory and office blood pressure: a HOPE substudyHypertension200138E283211751742
   PubMed Web of Science ®Google Scholar
• WachtellKHornestamBLehtoMCardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) StudyJ Am Coll Cardiol2005457051115734614
   PubMed Web of Science ®Google Scholar
• WaeberBCombination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertensionExpert Rev Cardiovasc Ther20031435015030296
   PubMedGoogle Scholar
• WaldNJLawMRA strategy to reduce cardiovascular disease by more than 80%BMJ2003 326:1419. Erratum in BMJ, 2003. 327:586 and BMJ, 2006. 60:823
   Google Scholar
• WarlowCPEpidemiology of strokeLancet1998352S14
   PubMed Web of Science ®Google Scholar
• WeinbergerMHBlood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patientsJ Cardiovasc Pharmacol19857Suppl 1S5252580177
   PubMedGoogle Scholar
• WilliamsBRecent hypertension trials: implications and controversiesJ Am Coll Cardiol2005458132715766813
   PubMed Web of Science ®Google Scholar
• WolfPAD’AgostinoRBBelangerAJProbability of stroke: a risk profile from the Framingham StudyStroke19912231282003301
   PubMed Web of Science ®Google Scholar
• WolfPAD’AgostinoRBO’NealASecular trends in stroke incidence and mortality. The Framingham StudyStroke199223155151440701
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA20032892363912746359
   PubMed Web of Science ®Google Scholar
• WolzMCutlerJRoccellaEJStatement from the National High Blood Pressure Education Program: prevalence of hypertensionAm J Hypertens200013103410678279
   PubMed Web of Science ®Google Scholar
• WrightJTJrProfile of systemic hypertension in black patientsAm J Cardiol19886141H45H
   PubMed Web of Science ®Google Scholar